Anika Therapeutics posted a third quarter that looks better on the top line than on the bottom line. On Earnings Whispers' normalized basis, the company lost $0.01 per share against a consensus estimate for a $0.02 profit, a 150.0% miss. Revenue of $30.59 million beat the $29.44 million consensus by 3.9% and rose 10.0% year over year. Earnings improved 94.1% from a year ago as last year's sizable loss nearly disappeared. The press release reports a GAAP loss from continuing operations of $0.02 per share and adjusted EPS of $0.29, so investors will see very different per-share figures depending on the lens. The central tension is that this was the first quarter of 2026 that read as balanced rather than a clean beat-and-raise. A higher total-company guidance floor and a lucrative partner renewal arrived alongside a commercial-channel cut, a sequential margin step-down and a regulatory setback.

The quality of the quarter deserves scrutiny. Year-over-year improvement was substantial. Gross margin expanded to 62% from 56%, the GAAP operating loss narrowed to $0.7 million from $3.2 million, and adjusted EBITDA rose to $5.1 million from $0.9 million. The sequential picture is weaker:

• Gross margin slipped from 65% in Q2 and 64% in Q1, pressured by mix from the reintroduced Hyalomatrix wound product.
• Adjusted EBITDA fell from $7.1 million in Q2, which management attributed to OEM shipment timing.
• OEM growth decelerated to 5% after 14% in each of the first two quarters.

The gap between GAAP and adjusted earnings also matters. Stock-based compensation nearly doubled year over year to $4.2 million in the quarter and reached $12.7 million year to date. That is a real cost the $0.29 adjusted figure excludes.

The commercial business remains the growth engine, though not quite at the pace management hoped. Commercial Channel revenue rose 17% to a record $14.0 million. International OA pain management grew 19%, and Integrity rose more than 30%, bringing trailing-12-month revenue to $7.5 million. Even so, management cut 2026 Commercial Channel growth guidance to 9%-13% from 12%-18%. It cited softer U.S. elective surgery volumes and Integrity running below plan. OEM guidance moved the other way, to 5%-9% from 0%-5%. That lifted total-company growth to 6%-10% and the adjusted EBITDA margin range to 15%-17%. The mix of that raise is less flattering than the headline suggests. The more strategic, higher-growth channel was trimmed, while the channel management expects to be flat to modestly lower in 2027 carried the upgrade. On the call, the CEO also reframed near-term gross margin expectations to the "low 60s" from "mid-60s" commentary in Q2.

The forward catalysts are tangible. The new 10-year Hyvisc agreement with Boehringer Ingelheim brings:

• higher transfer pricing;
• a royalty on end-market sales;
• higher contractual purchases;
• $8 million in total payments, including $4 million upfront expected in Q1 2027.

Cingal bioequivalence enrollment wrapped up in September, and an NDA submission is now targeted before year-end 2027. Capacity also expanded through a newly FDA-approved aseptic process and a second validated cross-link filler. Bears have legitimate ammunition, however. The FDA deemed the Hyalofast PMA not approvable, primarily on clinical data, which likely means more evidence and more time. Management also reaffirmed only flat-to-5% total growth for 2027 and expects U.S. OA pricing declines that year. Cash generation improved in the quarter, with $8.4 million of operating cash flow per the call. Year to date, though, operating cash flow is just $2.8 million because inventory swelled to $30.4 million from $18.8 million. Over the same period, the company spent $9.5 million on buybacks.

Investor sentiment had already cooled meaningfully before the report. The Earnings Whispers reading fell from 0.27 at the prior report to roughly neutral at 0.005. That suggests the bullish enthusiasm following Q2 had largely drained away. The stock tells a related story. Shares closed at $19.33 ahead of the release, up 12.2% from the open after the July report and about 19% above the 200-day moving average. However, they sat 15.5% below the $22.88 52-week high set on August 10, meaning a good portion of the post-Q2 rally had been surrendered heading into this print.

The bottom line is that Anika's operating turnaround is real on a year-over-year basis. Gross margin, adjusted EBITDA and operating losses all improved sharply, and the Boehringer deal adds durable economics. Still, this quarter marked a downshift in momentum. The EPS miss, the sequential margin and EBITDA declines, the trimmed commercial outlook and the Hyalofast rejection temper the growth narrative. With sentiment already neutralized and the stock well off its summer high, the setup now hinges on whether Integrity and international demand can reaccelerate commercial growth while margins hold in the low 60s.